Non-adjuvanted RSV vaccine (Abrysvo) in pregnant people

Coversheet

Coversheet on evidence assessment by ATAGI using the GRADE framework for Abrysvo (Pfizer) RSV vaccines in pregnant women

ATAGI recommendations

Comparison of Pfizer RSV bivalent pre-fusion F vaccine (Abrysvo) with placebo or no vaccine in pregnant women at 24 to 36 weeks gestation

 

Adjuvanted RSV vaccine (Arexvy) and non-adjuvanted RSV vaccine (Abrysvo) in older people

Coversheet

Coversheet on evidence assessment by ATAGI using the GRADE framework for Arexvy (GSK) and Abrysvo (Pfizer) RSV vaccines in adults aged ≥60 years 

ATAGI recommendations

PICO 1 Comparison of GSK AS01E adjuvanted RSVPreF3 vaccine (Arexvy) with placebo or no vaccine in adults aged ≥60 years

PICO 2 Comparison of RSV pre-fusion F protein (Abrysvo) vaccine with placebo in adults aged ≥60 years 

 

Adjuvanted RSV vaccine (Arexvy) in adults aged 50–59 years with medical risk factors for severe disease

Coversheet

Coversheet on evidence assessment by ATAGI using the GRADE framework for Arexvy RSVPreF3 vaccine adjuvanted with AS01E in adults aged 50–59 years

ATAGI recommendations

Comparison of GSK RSVPreF3 (Arexvy) vaccine adjuvanted with AS01E with placebo or no vaccine in adults aged 50–59 years

 

Nirsevimab (Beyfortus) RSV monoclonal antibody in infants aged <8 months born during or entering their first RSV season

Coversheet

Coversheet on evidence assessment by ATAGI using the GRADE framework for nirsevimab (Beyfortus) in infants aged <8 months born during or entering their first RSV season

ATAGI recommendations

Comparison of nirsevimab (Beyfortus) with placebo or no nirsevimab in infants aged <8 months born during or entering their first RSV season

 

Last updated July 2025